Autoimmune Encephalitis clinical trials at UCSF
1 research study open to eligible people
Autoimmune encephalitis is brain inflammation caused by an immune attack on brain cells. UCSF is studying an injectable antibody treatment for people with anti-NMDAR or anti-LGI1 antibodies. The trials record safety, drug behavior, and clinical effects.
Showing trials for
(PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis
open to eligible people ages 12 years and up
The purpose of this study is to assess the efficacy, safety, PK, and PD of satralizumab in participants with NMDAR and LGI1 encephalitis.
San Francisco, California and other locations
Our lead scientists for Autoimmune Encephalitis research studies include Jeffrey Gelfand.
Last updated: